Follow-on Offering

Healthcare
Follow-on Offering

Summary

Baird served as joint bookrunning manager on this offering

About

Exact Sciences Corporation (“Exact Sciences” or the “Company”) (NASDAQ: EXAS) recently completed a follow-on offering of 7,000,000 shares of common stock at $35.00 per share, generating gross proceeds of approximately $245 million. Exact Sciences has granted to the underwriters of the offering a 30-day option to purchase up to an additional 1,050,000 shares of common stock. The Company intends to use the net proceeds of this offering to fund expansion of its Cologuard commercialization activities including to increase its laboratory, manufacturing and customer service capacity, to fund its product development efforts, and for general corporate and working capital purposes.

Exact Sciences is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The Company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Exact Sciences is based in Madison, Wisconsin.
CONTACT US TO LEARN MORE
Healthcare
Follow-on Offering
Date
June 2017
Company
Exact Sciences Corporation
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share